Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands

Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands

Ziihera’s opportunity is expanding: Jazz raised its estimated annual revenue potential for zanidatamab from more than $2 billion to $3 billion–$5 billion , citing possible uses in gastric, breast, colorectal and biliary tract cancers.

New Ziihera data showed statistically significant overall-survival benefits for both combination-treatment arms, while ongoing trials could support additional approvals, including in colorectal cancer and potentially tumor-agnostic HER2-positive cancers.

Jazz is broadening its pipeline beyond oncology, launching four new EPIDIOLEX epilepsy studies and advancing next-generation treatments for epilepsy, sleep disorders and high-grade glioma.

Jazz Pharmaceuticals NASDAQ: JAZZ outlined development and commercial plans for its oncology, epilepsy and sleep franchises during a discussion with Deutsche Bank analyst David Hoang, emphasizing the expansion potential of HER2-targeted therapy Ziihera and ongoing lifecycle work for EPIDIOLEX.

An unnamed Jazz executive said zanidatamab, marketed as Ziihera, produced a statistically significant overall-survival result for its zanidatamab-plus-chemotherapy arm versus a control arm in a second interim analysis.

The company had previously reported a statistically significant overall-survival benefit for a triplet regimen that included zanidatamab, chemotherapy and the PD-1 inhibitor tislelizumab.

The executive said hazard ratios for both experimental arms improved from the first interim analysis and characterized the trend as consistent with the durable benefits that may emerge over time with highly immune-active drugs.

Jazz expects to present the data at an upcoming medical conference.

Jazz is continuing several Ziihera studies, including:

A frontline biliary tract cancer trial.

A pivotal later-line breast cancer trial.

A pan-tumor trial intended to support a possible tumor-agnostic indication for HER2-overexpressing tumors that have not responded to standard therapies.

The company said colorectal cancer findings from its broader program, along with other data, supported an FDA breakthrough therapy designation in second-line colorectal cancer.

Jazz said it is discussing a potential approval pathway in colorectal cancer with the FDA and may also pursue opportunities in non-small cell lung cancer.

In explaining its interest in zanidatamab, the executive pointed to its biparatopic HER2-antibody design, which targets two binding sites on the receptor.

According to the company, the design can drive receptor clustering and internalization, activate the complement cascade and recruit immune cells.

Jazz said those characteristics may help explain activity in PD-L1-negative gastric cancer patients and support the potential for combination treatment with PD-1 inhibitors.

Jack Spinks, Executive Director of Investor Relations at Jazz, said the company estimates an annual incidence of roughly 8,000 HER2-positive gastroesophageal adenocarcinoma patients, while its estimate of 3,000 to 4,000 treatable patients accounts for unresectable disease, first-line treatment and testing rates.

Spinks said Ziihera had launched three weeks earlier and that Jazz expects the therapy to become a first-line standard of care.

The company said it believes zanidatamab should replace trastuzumab in first-line HER2-positive gastroesophageal adenocarcinoma, with most patients receiving the triplet regimen including tislelizumab.